InvestorsHub Logo
Followers 1
Posts 45
Boards Moderated 0
Alias Born 08/16/2020

Re: Demogod post# 29124

Tuesday, 11/03/2020 3:20:53 PM

Tuesday, November 03, 2020 3:20:53 PM

Post# of 44695
Apparently related to different VIP receptors VPAC1 and VPAC2. PhaseBio's targeted VPAC2 (and RLF targets VPAC1).

https://pubchem.ncbi.nlm.nih.gov/substance/135651911

Difference between VPAC1&2:

https://en.m.wikipedia.org/wiki/Vasoactive_intestinal_peptide_receptor

Sorry if old news here.

...So lack of results for PhaseBio really has no bearing on possible results with Relief's efforts.